Guselkumab induced greater clinical and endoscopic improvements in patients with Crohn’s disease versus placebo, with a favourable safety profile in this Phase 2 trial by Sandborn, et al.

GALAXI-1 was a Phase 2, double-blind, placebo-controlled study where patients were randomised 1:1:1:1:1 to placebo, guselkumab 200mg, guselkumab 600mg, guselkumab 1200mg, or ustekinumab and observed up to 12 weeks. The primary endpoint was a change from baseline in CDAI score at Week 12.